Chemed Secures $450M Revolving Credit Facility with Expansion Option
Event summary
- Chemed Corp. amended its credit agreement to a five-year $450M revolving facility, including $100M for letters of credit.
- The deal includes a floating interest rate tied to SOFR plus a tiered rate based on leverage ratio.
- An expansion feature allows Chemed to increase the revolver by an additional $250M.
- JPMorgan Chase Bank, N.A. served as Administrative Agent and Joint Lead Arranger, with Bank of America, N.A. as Joint Lead Arranger and Syndication Agent.
The big picture
Chemed's move to secure a larger, more flexible credit facility reflects a strategic pivot to bolster liquidity amid evolving market conditions. The healthcare and home services sectors are increasingly capital-intensive, and this financing positions Chemed to navigate operational demands while maintaining financial agility. The inclusion of an expansion feature underscores the company's intent to remain adaptable in a dynamic economic landscape.
What we're watching
- Debt Management
- How Chemed will utilize the expanded credit facility to support its two distinct business segments, VITAS Healthcare and Roto-Rooter.
- Interest Rate Risk
- Whether the floating-rate structure will expose Chemed to volatility as SOFR fluctuates.
- Strategic Flexibility
- The pace at which Chemed may exercise the $250M expansion option and the potential impact on its capital structure.
Related topics